Protara Therapeutics, Inc.

TARA

Healthcare Biotechnology

EPS
−2.86%
Free cash flow
−28.1%

Quarter to June 2026, against a year earlier

2.30 0.17 +7.98%
Market cap
$135.9M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−255.1%
Net debt / EBITDA
2.4×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(45.80%) (37.27%) (31.60%) (49.42%)

+8 more TTM periods

ROA
(42.05%) (35.12%) (29.39%) (44.32%)
ROIC
(255.06%) (96.39%) (98.74%) 0.00%
Return on Tangible Assets
(52.19%) (48.05%) (38.47%) (41.80%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(1.09) (1.09) (1.32) (1.15)
Free Cash Flow
(66.52) (62.99) (56.46) (48.79)
Other line items

Show all line items

Columns are period end dates